AXSM:NSC-Axsome Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 76.79

Change

-1.33 (-1.70)%

Market Cap

USD 0.14B

Volume

0.68M

Analyst Target

USD 162.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Axsome Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapies for the management of pain and other central nervous system, or CNS, disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 110.51B
MRNA Moderna Inc

N/A

USD 57.87B
BNTX BioNTech SE

N/A

USD 24.18B
ARGX argenx NV ADR

N/A

USD 23.04B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.29B
GMAB Genmab AS

N/A

USD 18.17B
BGNE BeiGene Ltd

N/A

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.32B

ETFs Containing AXSM

XPH SPDR® S&P Pharmaceutical.. 4.68 % 0.35 %

N/A

USD 0.20B
DWAQ 0.00 % 0.60 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

USD 0.01B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

N/A

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.52% 52% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.52% 52% F 42% F
Trailing 12 Months  
Capital Gain 11.73% 70% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.73% 70% C- 62% D
Trailing 5 Years  
Capital Gain 210.51% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 210.51% 91% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 44.29% 85% B 89% A-
Dividend Return 44.29% 85% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 93.90% 28% F 17% F
Risk Adjusted Return 47.16% 92% A 78% C+
Market Capitalization 0.14B 94% A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 17.15 8% 6%
Price / Cash Flow Ratio -25.57 95% 90%
Price/Free Cash Flow Ratio -13.67 92% 87%
Management Effectiveness  
Return on Equity -231.68% 21% 10%
Return on Invested Capital -64.19% 46% 18%
Return on Assets -32.76% 47% 16%
Debt to Equity Ratio 93.24% 22% 25%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector